<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03365700</url>
  </required_header>
  <id_info>
    <org_study_id>IRON2017</org_study_id>
    <nct_id>NCT03365700</nct_id>
  </id_info>
  <brief_title>Cryoballon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation</brief_title>
  <acronym>IRON-ICE</acronym>
  <official_title>Cryoballon Versus Conventional Radiofrequency Ablation for Persistent Atrial Fibrillation With AF Duration &lt; 2 Years: the IRON-ICE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luigi Sacco University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luigi Sacco University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized trial has recently demonstrated non-inferiority of cryoballoon vs.
      radiofrequency (RF) catheter ablation in patients with drug-refractory paroxysmal atrial
      fibrillation (AF). There is a growing amount of evidence suggesting that Cryoballoon ablation
      is highly effective also in non-paroxysmal atrial fibrillation.

      The IRON-ICE trial will evaluate the effect of Cryoballoon AF ablation in patients with
      short-term persistent AF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from atrial tachycardia/fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from atrial tachycardia/fibrillation within 12 months after CA. Arrhythmias had to last 30 seconds or more to be considered present.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of AF episodes recorded.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of AF episodes recorded.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of postoperative hospital stay.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedural time.</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrial instrumentation time</measure>
    <time_frame>1 day</time_frame>
    <description>total time during which there are catheters in the LA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations after discharge.</measure>
    <time_frame>12 months</time_frame>
    <description>number of hospitalizations after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure-related complications</measure>
    <time_frame>1 week</time_frame>
    <description>Complications: cerebrovascular (thromboembolic or hemorrhagic), cardiovascular (cardiac perforation, tamponade) or gastrointestinal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cerebrovascular events from the time of the operation up to 90 days.</measure>
    <time_frame>90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term success</measure>
    <time_frame>36 months</time_frame>
    <description>freedom from AF/AFL/AT recurrences following the 3-month blanking period within 36-month follow-up from the date of the ablation procedure in the absence of Class I and III antiarrhythmic drug therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from clinical or stroke-relevant AF/AFL/AT.</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from AF/AFL/AT with duration cutoff &gt; 1 hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from persistent AF/AFL/AT (duration cutoff of 7 days)</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from AF/AFL/AT with duration cutoff &gt; 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regression from persistent to non-paroxysmal atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>Patients converted into paroxysmal forms of AF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant reduction in AF burden</measure>
    <time_frame>12 months</time_frame>
    <description>&gt;75% reduction from pre- to postablation and/or total postablation burden &lt;12%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low daily AF burden</measure>
    <time_frame>12 months</time_frame>
    <description>Patients with AF burden less than 1%- 2%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">303</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contact force-sensing radiofrequency left atrial ablation with 3D mapping system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency Ablation</intervention_name>
    <description>Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.</description>
    <arm_group_label>Radiofrequency Ablation</arm_group_label>
    <other_name>Pulmonary vein isolation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoballoon ablation</intervention_name>
    <description>Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.</description>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
    <other_name>Pulmonary vein isolation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Candidates for AF ablation based on AF that is symptomatic and refractory to at least
             one antiarrhythmic medication.

          2. Patients presenting with Persistent AF with AF duration &lt; 2 years scheduled to undergo
             a PVAI procedure

          3. Age range of 18 - 85 years

          4. Patients with already implanted devices with AF detection capabilities (for clinical
             indications): ILR implanted in the same hospital stay or within 6 months before the
             ablation or patients with an dual chamber PM, ICD or CRTD and an existing functional
             atrial lead.

          5. Patients must be able and willing to provide written informed consent to participate
             in the clinical trial.

        Exclusion Criteria:

          -  Congenital heart disease, age younger than 18 years, significant valve disease, LA
             size &gt;55 mm, and severe heart failure (ejection fraction &lt; 30% and/or New York Heart
             Association class IV).

          -  Presence of a mechanical prosthetic valve.

          -  Secondary causes of atrial fibrillation

          -  Documented intra-atrial thrombus or another abnormality which precludes catheter
             introduction.

          -  Social factors that would preclude follow up or make compliance difficult.-

          -  Patients who are or may potentially be pregnant Previous left atrial catheter ablation
             or MAZE procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Tondo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Rhythm Center at Monzino Cardiac Center, IRCCS.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanni B Forleo, MD, PhD</last_name>
    <phone>+390239042789</phone>
    <email>gbforleo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Polo Universitario - &quot;Luigi Sacco&quot;</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni B Forleo, MD, PhD</last_name>
      <email>gbforleo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heart Rhythm Center at Monzino Cardiac Center, IRCCS.</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Tondo, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Gaetano Fassini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico S. Ambrogio</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Mantica, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Kuck KH, Fürnkranz A, Chun KR, Metzner A, Ouyang F, Schlüter M, Elvan A, Lim HW, Kueffer FJ, Arentz T, Albenque JP, Tondo C, Kühne M, Sticherling C, Brugada J; FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016 Oct 7;37(38):2858-2865. Epub 2016 Jul 5.</citation>
    <PMID>27381589</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuck KH, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KR, Elvan A, Arentz T, Bestehorn K, Pocock SJ, Albenque JP, Tondo C; FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45. doi: 10.1056/NEJMoa1602014. Epub 2016 Apr 4.</citation>
    <PMID>27042964</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Luigi Sacco University Hospital</investigator_affiliation>
    <investigator_full_name>Giovanni B Forleo</investigator_full_name>
    <investigator_title>Section Head Electrophysiology and Cardiac Pacing.</investigator_title>
  </responsible_party>
  <keyword>Persistent atrial fibrillation</keyword>
  <keyword>Catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

